Currently in shortage
Global demand for dupilumab across atopic dermatitis, asthma and nasal polyps indications exceeding Sanofi production capacity.
Expected resolution: 31 October 2025
Alternatives:
- Discuss alternative biologics with dermatologist or allergist
- Protopic (tacrolimus) ointment for localised eczema
dupilumab
Dupixent
300 mg/2 mL · injection · Eczema
PBS Pricing
| General patient co-payment | $31.60 |
| Concession co-payment | $7.70 |
| Full dispensed price | $2,480.00 |
PBS Information
- Item code
- DER011
- Drug name
- dupilumab
- Brand name
- Dupixent
- Manufacturer
- Sanofi
- Formulation
- injection
- Strength
- 300 mg/2 mL
- Max quantity
- 2 units
- Max repeats
- 5
- PBS listed
- Yes
- Therapeutic group
- Eczema
TGA Reference: TGA-MSI-2025-038 · Sponsor: Sanofi-Aventis Australia Pty Ltd
MedWatch is for informational purposes only and does not constitute medical advice. Never stop or change your medicines without consulting your doctor or pharmacist. In an emergency, call 000. Medication queries: National Medicines Line 1300 633 424.